Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702669 | 1.00 | BTK (0.31) | BTKGPBAR1CACNA1BHTR2AHTR2C | |
| SCHEMBL701471 | 0.94 | HTR2A (0.33) | BTKGPBAR1HTR2AHTR2CCRHR1 | |
| SCHEMBL701470 | 0.94 | HTR2A (0.33) | BTKGPBAR1HTR2AHTR2CCRHR1 | |
| SCHEMBL700247 | 0.91 | PTGDR2 (0.34) | BTKCACNA1BHTR2AHTR2C | |
| SCHEMBL700249 | 0.91 | PTGDR2 (0.34) | BTKCACNA1BHTR2AHTR2C | |
| SCHEMBL732963 | 0.91 | CETP (0.35) | BTKGPBAR1HTR2AHTR2CCRHR1 | |
| SCHEMBL701711 | 0.90 | GCK (0.32) | BTKGPBAR1 | |
| SCHEMBL701709 | 0.90 | GCK (0.32) | BTKGPBAR1 | |
| SCHEMBL2625189 | 0.90 | ALDH1A1 (0.31) | BTKGPBAR1 | |
| SCHEMBL701710 | 0.89 | GPBAR1 (0.35) | BTKGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | claimed |
| JP-2011528002-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2307382-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| WO-2010006939-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | claimed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| WO-2010006939-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | BTK 3943/4885GPBAR1 92/4885CACNA1B 1996/4885 |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | BTK 3943/4885GPBAR1 92/4885CACNA1B 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.